ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
•26 Jun 2026 04:23

Circuit Fabology H Share Listing (9630 HK): Trading Debut

Circuit Fabology priced its H Share at HK$252.73, raising HK$3,245 million (US$414 million) in gross proceeds. The international oversubscription...

Logo
125 Views
Share
bullish•Lingyi iTech
•26 Jun 2026 03:11

Lingyi ITech H Share Listing (1688 HK): Trading Debut

Lingyi iTech priced its H Share at HK$10.18, raising HK$8,264 million (US$1.1 billion) in gross proceeds. The implied 50.6% AH discount is attractive

Logo
118 Views
Share
bullish•SG Micro
•25 Jun 2026 22:34

SG Micro H Share Listing (3661 HK): Trading Debut

SG Micro priced its H Share at HK$85.20, raising HK$4,601 million (US$587 million) in gross proceeds. The current AH discount of 46.5% is attractive.

Logo
148 Views
Share
•24 Jun 2026 07:30

Anker Innovations (668 HK) IPO: A Safe Play

​Anker Innovations' IPO is reasonably priced with strong growth prospects at a projected 3-year earnings CAGR of 20.7%. This is a potential 16.6%...

Logo
234 Views
Share
•23 Jun 2026 15:24

Anker Innovations H Share Listing (668 HK): Valuation Insights

Anker Innovations, a leading global provider of core offshore wind power equipment, has launched an H Share listing to raise US$590 million. In...

Logo
209 Views
Share
x